Clozapine vs Risperidone (Uzedy)

Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.

Schizophrenia

Shared mechanism: Dopamine D2 and serotonin 5-HT2A receptors (antagonist) · full Schizophrenia pipeline

Clozapine

Marketed by HLS Therapeutics Inc.

Approved in Schizophreniasmall molecule
Weak signal

NCT00250575 · Phase 3 · completed

The study was open-label, single-arm, and had no placebo or active comparator; all 43 participants received clozapine. Its primary measures focused on hematological tests, blood-related adverse events, and monitoring-system compliance rather than a clinical symptom endpoint, and no results are posted.

Next expected readout: April 2027 · NCT04580134 (registry estimate)

Reported efficacy

Treatment efficacy rate (baseline,0.5 months,1 months, 2 months,4 months , 6 months , 8 months and 12 months); All-cause dropout rate (baseline,0.5 months,1 months, 2 months,4 months , 6 months , 8 months and 12 months): Primary 1, symptomatic response (40% or more PANSS total reduction) in phase 2 among 111 re-randomized nonresponders: clozapine 62.5% (20/32) vs amisulpride 44.7% (17/38) vs olanzapine 31.7% (13/41) (chi-square 6.9; P=.03), met. Primary 2, time to all-cause discontinuation: the paper reports no clear difference between treatment groups, missed. (mixed)

Result source: NCT03510325

Risperidone (Uzedy)

Marketed by Teva Pharmaceutical Industries and partners

Approved in Schizophreniasmall molecule
Reliable signal

NCT03503318 · Phase 3 · completed

This was a randomized, quadruple-blind, placebo-controlled trial with 544 participants assigned to placebo, monthly TV-46000, or every-two-month TV-46000. The hard clinical primary endpoint was time to impending relapse, and it was statistically significantly favorable for both monthly treatment (13/183 vs 53/181; p<0.0001) and every-two-month treatment (23/179 vs 53/181; p<0.0001).

Reported efficacy

Time to Impending Relapse (Number of Participants With Impending Relapse) for Intent-to-treat [ITT] Analysis Set (From randomization up to 108 weeks): Time to Impending Relapse (Number of Participants With Impending Relapse) for Intent-to-treat [ITT] Analysis Set (From randomization up to 108 weeks): TV-46000 q1m 13/183 | TV-46000 q2m 23/179 vs Placebo 53/181 (met)

Result source: NCT03503318

Results for Schizophrenia

Values come from each drug's own ClinicalTrials.gov study. They are from separate trials and patient populations, not a head-to-head comparison. Each result identifies its source trial, phase, arm and timepoint; limitations that apply to a whole cell are marked with a letter and listed once beneath the table. The comparison is deepest for later-stage drugs (phase 3 or approved), which usually have posted results to draw on; early-stage drugs often have none yet.

These assets measured different things. Their trials share no endpoint in common, so no efficacy row can be built. That is a property of the programmes rather than a gap in the record: each asset's own reported endpoints are listed below.

Key endpointClozapineRisperidone (Uzedy)
PANSS total, change—Not posted · NCT00649844—Not posted · NCT00159770
CGI-S, change—Not posted · NCT00649844—Not posted · NCT00159770
PANSS response—Not posted · NCT00649844—Not posted · NCT00159770
PSP, change—Not posted · NCT00649844—Not posted · NCT00159770
Relapse (% of patients)—Not posted · NCT006498447.1% vs 29.3%−22.2 vs placeboq1m · n 183NCT03503318
7 other results
  • 12.8% vs 29.3% q2m · n 179 · Phase 3 · primary NCT03503318
  • 0.1% vs 0.3% q1m · wk 24 · n 183 · Phase 3 · secondary NCT03503318
  • 0.1% vs 0.3% q2m · wk 24 · n 179 · Phase 3 · secondary NCT03503318
  • 7.1% vs 29.3% q1m · n 183 · Phase 3 · secondary NCT03503318
  • 13.3% vs 29.3% q2m · n 180 · Phase 3 · secondary NCT03503318
  • 7.1% vs 29.3% q1m · n 183 · Phase 3 · secondary NCT03503318
  • 12.8% vs 29.3% q2m · n 179 · Phase 3 · secondary NCT03503318

PANSS total, change

Clozapine
—Not posted · NCT00649844
Risperidone (Uzedy)
—Not posted · NCT00159770

CGI-S, change

Clozapine
—Not posted · NCT00649844
Risperidone (Uzedy)
—Not posted · NCT00159770

PANSS response

Clozapine
—Not posted · NCT00649844
Risperidone (Uzedy)
—Not posted · NCT00159770

PSP, change

Clozapine
—Not posted · NCT00649844
Risperidone (Uzedy)
—Not posted · NCT00159770

Relapse (% of patients)

Clozapine
—Not posted · NCT00649844
Risperidone (Uzedy)
7.1% vs 29.3%−22.2 vs placeboq1m · n 183NCT03503318
7 other results
  • 12.8% vs 29.3% q2m · n 179 · Phase 3 · primary NCT03503318
  • 0.1% vs 0.3% q1m · wk 24 · n 183 · Phase 3 · secondary NCT03503318
  • 0.1% vs 0.3% q2m · wk 24 · n 179 · Phase 3 · secondary NCT03503318
  • 7.1% vs 29.3% q1m · n 183 · Phase 3 · secondary NCT03503318
  • 13.3% vs 29.3% q2m · n 180 · Phase 3 · secondary NCT03503318
  • 7.1% vs 29.3% q1m · n 183 · Phase 3 · secondary NCT03503318
  • 12.8% vs 29.3% q2m · n 179 · Phase 3 · secondary NCT03503318
  1. Each cell is from that drug's own trial. Trials differ in population, design and timepoint; this is not a head-to-head comparison.
  2. An empty cell names why: Not posted (a completed Phase 3 here has no posted results yet), Trial running, Pending review (we hold the result and are checking it) or Not reported.

Only safety results can currently be compared in this indication. Reviewed efficacy summaries, where available, are listed separately.

safety

Coverage. Clozapine: 3 of 4 rows · Risperidone (Uzedy): 4 of 4 rows. A dash means no reviewed, structured value is available for that endpoint in this indication.

Reported metricClozapineRisperidone (Uzedy)
Dropout rate
41.7%a
NCT01639872 · Phase 4 · registry result, not featured evidence
show 2 more results
0%
NCT00498550 · Phase 4 · registry result, not featured evidence
17.2%
NCT02404155 · Phase na · registry result, not featured evidence
21.3%q1ma
NCT03503318 · Phase 3 · monotherapy
show 3 more results
22.2%q2m
NCT03503318 · Phase 3 · monotherapy
22.4%q1m
NCT03893825 · Phase 3 · monotherapy
24.7%q2m
NCT03893825 · Phase 3 · monotherapy
Discontinued due to AEs
—a
NCT01639872 · Phase 4 · registry result, not featured evidence
show 2 more results
—
NCT00498550 · Phase 4 · registry result, not featured evidence
—
NCT02404155 · Phase na · registry result, not featured evidence
2.2%q1ma
NCT03503318 · Phase 3 · monotherapy
show 3 more results
1.1%q2m
NCT03503318 · Phase 3 · monotherapy
0%q1m
NCT03893825 · Phase 3 · monotherapy
1.2%q2m
NCT03893825 · Phase 3 · monotherapy
Serious AEs
13%a
NCT01639872 · Phase 4 · registry result, not featured evidence
show 2 more results
26.7%
NCT00498550 · Phase 4 · registry result, not featured evidence
6.9%
NCT02404155 · Phase na · registry result, not featured evidence
4.4%q1ma
NCT03503318 · Phase 3 · monotherapy
show 3 more results
5.6%q2m
NCT03503318 · Phase 3 · monotherapy
4.7%q1m
NCT03893825 · Phase 3 · monotherapy
6.8%q2m
NCT03893825 · Phase 3 · monotherapy
Most frequent reported AEs
a
other-sialorrhea 43.5%
weight gain 30.4%
sedation 21.7%
NCT01639872 · Phase 4 · registry result, not featured evidence
show 2 more results
gastrointestinal disorder - other: hypersalivation 66.7%
somnolence 60%
weight gain 40%
NCT00498550 · Phase 4 · registry result, not featured evidence
salivation 68.2%
sedation 52.9%
malaise 52.6%
NCT02404155 · Phase na · registry result, not featured evidence
q1ma
injection site nodule 6.6% (placebo 3.4%)
insomnia 6.6% (placebo 5.6%)
injection site pruritus 5.5% (placebo 2.2%)
NCT03503318 · Phase 3 · monotherapy
show 3 more results
q2m
injection site nodule 7.2% (placebo 3.4%)
weight increased 7.2% (placebo 3.4%)
injection site pain 6.7% (placebo 6.1%)
NCT03503318 · Phase 3 · monotherapy
q1m
injection site pain 5.2%
injection site nodule 1.7%
NCT03893825 · Phase 3 · monotherapy
q2m
injection site nodule 5.6%
injection site pain 4.3%
NCT03893825 · Phase 3 · monotherapy

Notes

  1. aPopulation comparability has not been reviewed for these studies.

Reported by one asset only

Endpoints only one of the selected assets measured, so there is nothing to compare them against.

Clozapine

Cannabis Use Intensity Joints Per 2.36 vs 2.35 Risperidone months @ 12wk
absolute value · months
NCT01639872 · Phase 4 · registry result, not featured evidence · converted to months from 10.21 weeks as posted
Cannabis Use Frequency Days Per 0.14 vs 0.15 Risperidone months @ 12wk
absolute value · months
NCT01639872 · Phase 4 · registry result, not featured evidence · converted to months from 4.26 days as posted
Cannabis Use Joints Per 0.02 per week
absolute value · per week
No placebo or comparator arm
NCT00498550 · Phase 4 · registry result, not featured evidence

Risperidone (Uzedy)

Relapse 7.1% (n=183) vs 29.3% (n=181) placeboq1m
event count · % of participants
NCT03503318 · Phase 3 · monotherapy · converted to % from 13 Participants as posted
show 7 more results
12.8% (n=179) vs 29.3% (n=181) placebo*q2m
NCT03503318 · Phase 3 · monotherapy · converted to % from 23 Participants as posted
7.1% (n=183) vs 29.3% (n=181) placebo*q1m
NCT03503318 · Phase 3 · monotherapy · converted to % from 13 Participants as posted
13.3% (n=180) vs 29.3% (n=181) placebo*q2m
NCT03503318 · Phase 3 · monotherapy · converted to % from 24 Participants as posted
0.07% (n=183) vs 0.28% (n=181) placebo @ 24wkq1m
NCT03503318 · Phase 3 · monotherapy
0.11% (n=179) vs 0.28% (n=181) placebo @ 24wkq2m
NCT03503318 · Phase 3 · monotherapy
7.1% (n=183) vs 29.3% (n=181) placebo*q1m
NCT03503318 · Phase 3 · monotherapy · converted to % from 13 Participants as posted
12.8% (n=179) vs 29.3% (n=181) placebo*q2m
NCT03503318 · Phase 3 · monotherapy · converted to % from 23 Participants as posted
Clinical Remission 21.3% (n=183) vs 16.6% (n=181) placeboq1m
responder rate · % of participants
NCT03503318 · Phase 3 · monotherapy · converted to % from 39 Participants as posted
show 1 more result
23.5% (n=179) vs 16.6% (n=181) placebo*q2m
NCT03503318 · Phase 3 · monotherapy · converted to % from 42 Participants as posted
Relapse 100% (n=1)q2m
event count · % of participants
No placebo or comparator arm
NCT03503318 · Phase 3 · monotherapy · converted to % from 1 Participants as posted
SQLS -4.5 vs 0.9 placebo scoreq1m
absolute change · score
Change at the Endpoint
NCT03503318 · Phase 3 · monotherapy
show 1 more result
-4.1 vs 0.9 placebo scoreq2m
Change at the Endpoint
NCT03503318 · Phase 3 · monotherapy
CDSS -0.3 vs -0.4 placebo scoreq1m
absolute change · score
Change at the End of Treatment
NCT03503318 · Phase 3 · monotherapy
show 1 more result
-0.8 vs -0.4 placebo scoreq2m
Change at the End of Treatment
NCT03503318 · Phase 3 · monotherapy

The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: Clozapine's landscape · Risperidone (Uzedy)'s landscape